Valeant Pharma beats forecasts, turns in profit

7 August 2013

Canadian drugmaker Valeant Pharmaceuticals International (TSX: VRX) announced second quarter financial results for 2013 reporting earnings of $10.9 million, or $0.03 per share, compared to a loss of $21.6 million, or $0.07 per share, in the like 2012 quarter.

Total revenue climbed 34% to $1.1 billion (up 41% excluding one-time items in second-quarter 2012), and Generally Accepted Accounting Principles (GAAP) earnings per share were $1.34, an increase of 54% excluding one-time items. Valeant received a one-time payment of $45 million in the second quarter of 2012 from GlaxoSmithKline for the US market launch of Potiga (ezogabine).

Analysts expected, on average, earnings of $1.28 per share on $1.09 billion in revenue, according to FactSet.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK